EU/EEA capacity for the surveillance of hepatitis B and C using molecular methods
In order to explore whether the current capacity for EU/EEA-wide molecular characterisation for surveillance of HBV and HCV is sufficient to be feasible and what gaps need to be addressed, a survey of EU/EEA Member States was conducted to assess their laboratory capacity and needs in relation to the molecular characterisation of hepatitis B and C.
Country mission Latvia: HIV, STI and hepatitis B and C
This report describes a country mission undertaken by ECDC in 2011 to Latvia, to address issues relating to HIV, STI and hepatitis B and C identified by the Latvian government.
Assessing the burden of key infectious diseases affecting migrant populations in the EU/EEA: Executive summary
Hepatitis B and C surveillance in Europe 2012
This is the second report on the enhanced surveillance of hepatitis B and C viral infections. It describes basic epidemiological features and trends of both diseases across countries in the EU/EEA for 2012.
HIV and hepatitis B and C in Latvia
At the request of the Ministry of Health in Riga, a team of experts from ECDC and the European Monitoring Centre for Drugs and Drug Addiction paid a technical visit to Latvia on 2–4 September 2014.
Effectiveness and cost-effectiveness of antenatal screening for HIV, hepatitis B, syphilis and rubella susceptibility
This literature review was conducted as part of a project evaluating the effectiveness of antenatal screening for HIV, hepatitis B, syphilis and rubella susceptibility in EU/EEA Member States.
Public health guidance on antenatal screening for HIV, hepatitis B, syphilis and rubella susceptibility in the EU/EEA – addressing the vulnerable populations
This publication aims to support the strengthening of antenatal screening programmes for HIV, hepatitis B, syphilis and rubella susceptibility in the general population and in groups identified as vulnerable to mother-to-child-transmission in the EU/EEA.